Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16849199 | 0.85 | — | — | |
| SCHEMBL811021 | 0.80 | — | — | |
| SCHEMBL1292520 | 0.79 | FFAR3 (0.65) | KDM4EKMT2AFFAR3CYP1A2OPRM1 | |
| SCHEMBL3225347 | 0.77 | KDM4E (0.39) | KDM4EKMT2AFFAR3CYP1A2 | |
| Hydrochloric Acid SCHEMBL1282695 | 0.77 | FFAR3 (0.62) | KDM4EKMT2AFFAR3CYP1A2OPRM1 | |
| SCHEMBL2397325 | 0.77 | KDM4E (0.54) | KDM4EKMT2AFFAR3CYP1A2 | |
| Hydrochloric Acid SCHEMBL23411575 | 0.75 | FFAR3 (0.59) | KDM4EKMT2AFFAR3CYP1A2OPRM1 | |
| Hydrochloric Acid SCHEMBL2708163 | 0.75 | KDM4E (0.52) | KDM4EKMT2AFFAR3CYP1A2 | |
| SCHEMBL13747397 | 0.75 | KDM4E (0.38) | KDM4EKMT2AFFAR3CYP1A2 | |
| SCHEMBL6865583 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022237676-A1 | PREPARATION AND APPLICATION OF SHP2 PHOSPHATASE INHIBITOR | 药雅科技(上海)有限公司 | 2022-11-17 | — | — | WO | disclosed |
| US-20210169970-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20210169969-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | VAN DER PLOEG LEONARDUS H T (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA SAS (FR) | 2021-06-03 | — | — | US | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10960046-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10954268-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190111105-A1 | Use of Melanocortins to Treat Insulin Sensitivity | IPSEN PHARMA S.A.S. (FR) | 2019-04-18 | — | — | US | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20140329743-A1 | Method of Treating Melanocortin-4 Receptor-Associated Disorders in Heterozygous Carriers | RHYTHM PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140011730-A1 | Melanocortin Receptor Ligands Modified with Hydantoin | IPSEN PHARMA S.A.S. (FR) | 2014-01-09 | — | — | US | disclosed |
| US-8563000-B2 | Melanocortin receptor ligands modified with hydantoin | IPSEN PHARMA S.A.S. (FR) | 2013-10-22 | — | — | US | disclosed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2560978-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2008147556-A2 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169970-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | KDM4E 858/4885KMT2A 269/4885FFAR3 215/4885 |
| US-20140011730-A1 | Melanocortin Receptor Ligands Modified with Hydantoin | MC4R, MC3R, MC1R | KDM4E 2610/4885KMT2A 2039/4885FFAR3 139/4885 |
| US-20210169969-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | MC4R, MC2R, MC5R | KDM4E 1715/4885KMT2A 2126/4885FFAR3 155/4885 |
| US-10960046-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | KDM4E 1687/4885KMT2A 1029/4885FFAR3 547/4885 |
| US-20140329743-A1 | Method of Treating Melanocortin-4 Receptor-Associated Disorders in Heterozygous Carriers | MC4R, MC1R, MC2R | KDM4E 3875/4885KMT2A 1451/4885FFAR3 1223/4885 |
| US-20190111105-A1 | Use of Melanocortins to Treat Insulin Sensitivity | MC4R, MC1R, MC3R | KDM4E 4248/4885KMT2A 4090/4885FFAR3 141/4885 |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | KDM4E 2610/4885KMT2A 2039/4885FFAR3 139/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | KDM4E 804/4885KMT2A 1554/4885FFAR3 1953/4885 |
| US-10954268-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | MC4R, MC1R, MC2R | KDM4E 3784/4885KMT2A 1291/4885FFAR3 1343/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | KDM4E 3204/4885KMT2A 977/4885FFAR3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.